Colleen Moretti

Active surveillance in sentinel lymph node positive melanoma could delay surgery but may result in the same risk of the cancer coming back.

Inlyta alone demonstrates longer progression-free survival compared to Inlyta in combination with carotuximab.

Ayvakit demonstrated more durable survival outcomes in patients with unresectable/metastatic platelet-derived growth factor receptor A D842V-mutant gastrointestinal stromal tumors than tyrosine kinase inhibitors.

Antibiotics, corticosteroids and proton pump inhibitors could cause negative impacts on survival in patients with non-small cell lung cancer who are receiving treatment with Keytruda.

A slower walking pace may be associated with a higher risk of mortality rate in survivors of cancer compared with their healthy matched peers, according to an expert.

Reintroducing treatment with Jakafi in patients with myelofibrosis after previous discontinuation extended overall survival compared to those patients who stopped permanently, although there was a substantial rate of permanent treatment discontinuation with this therapy.

Trodelvy has received accelerated approval from the FDA for the treatment of patients with advanced urothelial cancer.

Previously, Vidaza alone showed poor response rates for patients with TP53-mutated, myelodysplastic syndromes and acute myeloid leukemia, but adding the novel agent eprenetapopt improved response rates and overall survival in this patient population.

At four-year follow up, treatment with givinostat, a histone-deacetylase inhibitor, continued to be safe and effective with no serious or life-threatening side effects.

Polymerase (PARP) inhibitors continue to improve progression-free survival over placebo in women with recurrent, platinum-sensitive ovarian cancer.

Previously, treatments for patients with extensive-disease small cell lung cancer were limited with a poor prognosis. Researchers sought to investigate if Opdivo plus Yervoy or Opdivo alone would improve survival.

Rozlytrek continues to demonstrate clinical benefit for patients with ROS1 fusion-positive non-small cell lung cancer, which includes patients with central nervous system metastases.

There is a lot of hype on T-cell engagers and CAR T-cell therapy, but there are other new and exciting immunotherapies in myeloma not talked about that may be approved in the near future, according to an expert.

Keytruda in combination with chemotherapy has just received FDA approval for the treatment of patients with metastatic or locally advanced esophageal and gastroesophageal cancers.

For patients with B-cell lymphoma, the addition of Revlimid to standard R-CHOP did not improve progression-free survival nor event-free survival.

In clinical trials, Opdivo in combination with chemotherapy improved overall survival and progression-free survival compared to chemotherapy alone.

As the population ages, the incidence of older adults being diagnosed with lung cancer is increasing, though data on how to specifically treat this population are lacking.

Triple-negative breast cancer, which is found in 15%-20% of invasive breast cancers, is a challenge when it comes to treatment, but thanks to new drug approvals and therapy regimens, the treatment landscape has progressed in recent years, according to an expert.

With more than 4 million breast cancer survivors in the U.S., survivorship care and understanding what happens to patients after surviving is of the utmost importance. An expert explains some side effects survivors may experience and treatments to help.

The data, according to the study authors, confirm a recent Food and Drug Administration approval of the regimen and support its use in the front-line treatment of patients with advanced non-small cell lung cancer.

Patients with prostate and breast cancer may be unknowingly putting themselves at risk while taking herbs and supplements during chemotherapy and should consult their medical team before using them, according to an expert.

Following resection with radiotherapy increased survival rates for patients compared with those who did not receive the additional treatment.

Patients with oropharyngeal cancer demonstrate higher rates of ever performing, timing, number of partners and intensity in oral sex than matching participants, suggesting an association between behavior and diagnosis.

Sending a text message reminder to participants about their upcoming fecal immunochemical test improved previously poor adherence rates for colorectal cancer screening.

Front-line treatment with Opdivo plus Cabometyx improved health-related quality of life outcomes in patients with advanced renal cell carcinoma.

Theresa Germano sat down with HEAL® to discuss her journey with cancer, how her daughter became her hero and how listening to her body benefited her in the end.

Danielle Ripley-Burgess, a two-time colon cancer survivor, discusses why she wrote a book about her journey and how her experience strengthened her faith.

Survivors of adolescent or young adult cancer diagnosis experience a 20% higher risk of a psychotic episode and a 30% higher chance of an outpatient mental health visit compared to individuals with no history of cancer.

Patients with rectal cancer who maintain a clinical complete response – meaning they are found to have no evidence of disease – after three years, may not need as frequent surveillance after that point, due to a decreased chance of regrowth and metastases.

Patients with prostate cancer experienced no significant difference in quality of life when treated with two different types of radiation regimens, recent research has found.